Viral Burden and Clearance in Asymptomatic COVID-19 Patients.
COVID-19
asymptomatic
duration
viral burden
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
01
12
2021
accepted:
15
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Containing coronavirus disease 2019 (COVID-19) has been difficult, due to both the large number of asymptomatic infected individuals and the long duration of infection. Managing these challenges requires understanding of the differences between asymptomatic vs symptomatic patients and those with a longer duration of infectivity. Individuals from Los Angeles were tested for COVID-19, and a group positive for COVID-19 chose to have follow-up testing. Associations between symptoms and demographic factors, viral burden measured by cycle threshold (CT) value, and duration of polymerase chain reaction (PCR) positivity were analyzed. Eighteen point eight percent of patients were positive for COVID-19. Asymptomatic COVID-19-positive patients were significantly younger than symptomatic patients (2.6 years; We found important differences and similarities between asymptomatic and symptomatic COVID-19-positive patients, the most meaningful being a similar level of virus as measured by PCR, but a shorter duration of PCR positivity for asymptomatic patients. These findings suggest that asymptomatic patients may have more efficient clearance of virus, which may be relevant for management and screening.
Sections du résumé
Background
UNASSIGNED
Containing coronavirus disease 2019 (COVID-19) has been difficult, due to both the large number of asymptomatic infected individuals and the long duration of infection. Managing these challenges requires understanding of the differences between asymptomatic vs symptomatic patients and those with a longer duration of infectivity.
Methods
UNASSIGNED
Individuals from Los Angeles were tested for COVID-19, and a group positive for COVID-19 chose to have follow-up testing. Associations between symptoms and demographic factors, viral burden measured by cycle threshold (CT) value, and duration of polymerase chain reaction (PCR) positivity were analyzed.
Results
UNASSIGNED
Eighteen point eight percent of patients were positive for COVID-19. Asymptomatic COVID-19-positive patients were significantly younger than symptomatic patients (2.6 years;
Conclusions
UNASSIGNED
We found important differences and similarities between asymptomatic and symptomatic COVID-19-positive patients, the most meaningful being a similar level of virus as measured by PCR, but a shorter duration of PCR positivity for asymptomatic patients. These findings suggest that asymptomatic patients may have more efficient clearance of virus, which may be relevant for management and screening.
Identifiants
pubmed: 35493121
doi: 10.1093/ofid/ofac126
pii: ofac126
pmc: PMC8992297
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac126Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
JAMA Intern Med. 2020 Nov 01;180(11):1447-1452
pubmed: 32780793
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
Clin Cancer Res. 2006 Jan 1;12(1):107-16
pubmed: 16397031
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1059-1062
pubmed: 34351882
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
N Engl J Med. 2020 Dec 17;383(25):2407-2416
pubmed: 33176093
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1743-1747
pubmed: 33211678
Front Cell Infect Microbiol. 2020 Oct 06;10:575613
pubmed: 33123498
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Emerg Infect Dis. 2020 Jul;26(7):1624-1626
pubmed: 32240079
Int J Infect Dis. 2020 May;94:133-138
pubmed: 32247826
Sci Total Environ. 2020 Aug 1;728:138812
pubmed: 32335406
J Infect Dis. 2013 Apr 15;207(8):1281-5
pubmed: 23382573
J Infect Dis. 2016 Feb 1;213(3):407-10
pubmed: 26068783